NO20042035L - Forbedret anvendelse av antitumorforbindelse i kreftterapi - Google Patents

Forbedret anvendelse av antitumorforbindelse i kreftterapi

Info

Publication number
NO20042035L
NO20042035L NO20042035A NO20042035A NO20042035L NO 20042035 L NO20042035 L NO 20042035L NO 20042035 A NO20042035 A NO 20042035A NO 20042035 A NO20042035 A NO 20042035A NO 20042035 L NO20042035 L NO 20042035L
Authority
NO
Norway
Prior art keywords
cancer therapy
improved use
antitumor compound
antitumor
compound
Prior art date
Application number
NO20042035A
Other languages
English (en)
Inventor
Jose Jimeno
Ana Ruiz Casado
Eric Rowinsky
Manual Hidalgo
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of NO20042035L publication Critical patent/NO20042035L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
NO20042035A 2001-10-19 2004-05-18 Forbedret anvendelse av antitumorforbindelse i kreftterapi NO20042035L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34841401P 2001-10-19 2001-10-19
PCT/US2002/033548 WO2003039571A1 (en) 2001-10-19 2002-10-21 Improved use of antitumoral compound in cancer therapy

Publications (1)

Publication Number Publication Date
NO20042035L true NO20042035L (no) 2004-05-18

Family

ID=23367939

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042035A NO20042035L (no) 2001-10-19 2004-05-18 Forbedret anvendelse av antitumorforbindelse i kreftterapi

Country Status (15)

Country Link
US (1) US20050004018A1 (no)
EP (1) EP1435988A4 (no)
JP (1) JP2005509650A (no)
KR (1) KR20050038578A (no)
CN (1) CN1606449A (no)
AU (1) AU2002343548B2 (no)
BR (1) BR0213424A (no)
CA (1) CA2462502A1 (no)
HU (1) HUP0401903A3 (no)
IL (1) IL161430A0 (no)
MX (1) MXPA04003674A (no)
NO (1) NO20042035L (no)
PL (1) PL368458A1 (no)
RU (1) RU2306933C2 (no)
WO (1) WO2003039571A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EA005564B1 (ru) * 2000-11-06 2005-04-28 Фарма Мар, С.А. Эффективные противоопухолевые лекарственные средства
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
SI1689404T1 (sl) * 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CN1897949A (zh) * 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
AU2005261860A1 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
RU2359700C2 (ru) * 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
MX2008014404A (es) * 2006-05-12 2008-11-27 Pharma Mar Sa Tratamientos anticancer con combinacion de docetaxel y ecteinascidin.
SG178789A1 (en) * 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
CA2703026A1 (en) * 2007-10-19 2009-04-23 Rafael Rosell Costa Prognostic molecular markers for et-743 treatment
WO2010019952A2 (en) * 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
SG11201503774PA (en) 2012-11-13 2015-06-29 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
KR100518986B1 (ko) * 1999-11-15 2005-10-06 파르마 마르, 에스.에이. 아플리딘을 사용하여 암을 치료하는 방법
JP5219323B2 (ja) * 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
EA005564B1 (ru) * 2000-11-06 2005-04-28 Фарма Мар, С.А. Эффективные противоопухолевые лекарственные средства
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제

Also Published As

Publication number Publication date
AU2002343548B2 (en) 2007-11-08
MXPA04003674A (es) 2004-07-23
WO2003039571A1 (en) 2003-05-15
EP1435988A1 (en) 2004-07-14
JP2005509650A (ja) 2005-04-14
AU2002343548B8 (en) 2003-05-19
HUP0401903A3 (en) 2008-07-28
CA2462502A1 (en) 2003-05-15
HUP0401903A2 (hu) 2005-01-28
KR20050038578A (ko) 2005-04-27
PL368458A1 (en) 2005-03-21
US20050004018A1 (en) 2005-01-06
RU2004115110A (ru) 2005-03-10
CN1606449A (zh) 2005-04-13
RU2306933C2 (ru) 2007-09-27
EP1435988A4 (en) 2008-01-09
IL161430A0 (en) 2004-09-27
BR0213424A (pt) 2004-12-14

Similar Documents

Publication Publication Date Title
CY2019030I2 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
IL169594A0 (en) Treatment of cancer with 2-deoxyglucose
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EP1311262A4 (en) CANCER THERAPY THROUGH COMBINATION THERAPY
SI1292594T1 (en) Quinazoline derivatives for the treatment of tumours
IL164599A0 (en) Combination therapy for the treatment of cancer
EP1392818A4 (en) FOR THE TREATMENT OF CANCER DISEASES IN HUMAN CERTAIN IMMUNE RECEPTOR
EP1482970A4 (en) ANTICANCER THERAPY
IS6891A (is) Aðferðir við gjöf epóþílon hliðstæðna við meðferðkrabbameins
NO20034780D0 (no) Antiangiogenisk kombinasjonsterapi for behandling av kreft
EP1435988A4 (en) IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER
HUP0500424A2 (en) Combination therapy for the treatment of cancer
AU2003212634A8 (en) Compounds useful in the treatment of cancer
IL161059A0 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
NO20014228D0 (no) Radioaktiv cisplatin i behandling av cancer
AU2003231803A8 (en) Treatment of cancer with mefloquire
GB0226595D0 (en) Cancer therapy determination
GB0329416D0 (en) Treatment of cancer
EP1463511A4 (en) COMBINATORY ANTICANCER THERAPY
NO20042850L (no) Kreftbehandling
GB0129451D0 (en) Treatment of cancer
GB0125764D0 (en) Diagnosis of cervicasl cancer
AU2003217925A1 (en) Treatment of metastatic institute for cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application